Kristen Ambrose's most recent trade in Vertex Pharmaceuticals, Inc. was a trade of 1,241 Common Stock done at an average price of $479.6 . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vertex Pharma | Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 479.61 per share. | 26 Feb 2025 | 1,241 | 7,845 (0%) | 0% | 479.6 | 595,196 | Common Stock |
| Vertex Pharma | Kristen C. Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 480.95 per share. | 24 Feb 2025 | 884 | 9,086 (0%) | 0% | 481.0 | 425,160 | Common Stock |
| Vertex Pharma | Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 483.28 per share. | 24 Feb 2025 | 828 | 9,970 (0%) | 0% | 483.3 | 400,156 | Common Stock |
| Vertex Pharma | Kristen C. Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 455.06 per share. | 14 Feb 2025 | 671 | 10,798 (0%) | 0% | 455.1 | 305,345 | Common Stock |
| Vertex Pharma | Kristen C. Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 463.46 per share. | 14 Feb 2025 | 564 | 11,469 (0%) | 0% | 463.5 | 261,391 | Common Stock |
| Vertex Pharma | Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 2,080 | 12,033 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose C. | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 459.83 per share. | 10 Feb 2025 | 1,376 | 9,953 (0%) | 0% | 459.8 | 632,726 | Common Stock |
| Vertex Pharma | Kristen Ambrose C. | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 467.98 per share. | 10 Feb 2025 | 591 | 11,329 (0%) | 0% | 468.0 | 276,576 | Common Stock |
| Vertex Pharma | Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 2,566 | 10,066 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose C. | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 1,854 | 11,920 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 419.00 per share. | 01 Apr 2024 | 240 | 7,500 (0%) | 0% | 419 | 100,560 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 418.10 per share. | 01 Apr 2024 | 225 | 7,740 (0%) | 0% | 418.1 | 94,073 | Common Stock |
| Vertex Pharma | Ambrose Kristen | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 425.70 per share. | 23 Feb 2024 | 883 | 7,965 (0%) | 0% | 425.7 | 375,893 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 431.79 per share. | 23 Feb 2024 | 828 | 8,848 (0%) | 0% | 431.8 | 357,522 | Common Stock |
| Vertex Pharma | Ambrose Kristen | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 420.24 per share. | 09 Feb 2024 | 1,374 | 9,676 (0%) | 0% | 420.2 | 577,410 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 422.74 per share. | 09 Feb 2024 | 591 | 11,050 (0%) | 0% | 422.7 | 249,839 | Common Stock |
| Vertex Pharma | Ambrose Kristen | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 2,950 | 9,788 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Ambrose Kristen | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 1,853 | 11,641 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 329.82 per share. | 30 May 2023 | 289 | 6,838 (0%) | 0% | 329.8 | 95,318 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.74 per share. | 31 Mar 2023 | 176 | 7,127 (0%) | 0% | 313.7 | 55,218 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 287.25 per share. | 24 Feb 2023 | 982 | 7,528 (0%) | 0% | 287.3 | 282,080 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 289.12 per share. | 24 Feb 2023 | 502 | 8,510 (0%) | 0% | 289.1 | 145,138 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 288.68 per share. | 24 Feb 2023 | 183 | 7,345 (0%) | 0% | 288.7 | 52,828 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 289.62 per share. | 24 Feb 2023 | 42 | 7,303 (0%) | 0% | 289.6 | 12,164 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,950 | 9,012 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2023 | 2,566 | 6,062 (0%) | 0% | 0 | Common Stock | |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 271.68 per share. | 25 Apr 2022 | 104 | 3,496 (0%) | 0% | 271.7 | 28,255 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 269.51 per share. | 25 Apr 2022 | 83 | 3,600 (0%) | 0% | 269.5 | 22,369 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 268.46 per share. | 25 Apr 2022 | 80 | 3,683 (0%) | 0% | 268.5 | 21,477 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 267.37 per share. | 25 Apr 2022 | 60 | 3,763 (0%) | 0% | 267.4 | 16,042 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 263.09 per share. | 01 Apr 2022 | 137 | 3,823 (0%) | 0% | 263.1 | 36,043 | Common Stock |
| Vertex Pharma | Kristen Ambrose | SVP & Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 2,566 | 3,960 (0%) | 0% | 0 | Common Stock |